Study S001992

Therapeutic Effect of Semaglutide on Nonalcoholic Fatty Liver Disease in Obesity and/or Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05813249
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 180
Start: 2023-02-15
Primary completion: 2024-02-15
Lead sponsor: Zagazig University
Conditions: Non-alcoholic Fatty Liver Disease
Interventions: DRUG:Rybelsus Oral Product; DRUG:Ozempic Injectable Product; DRUG:Tocopherol and/or Actos
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

NAFLD regression [48 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.